Evidence map›Paper›PMID 40542358›Full record

ArticleMolecular neurodegeneration2025

Mutations in PSEN1 predispose inflammation in an astrocyte model of familial Alzheimer's disease through disrupted regulated intramembrane proteolysis.

Oliver J Ziff, Gustavo Morrone Parfitt, Sarah Jolly, Jackie M Casey, Lucy Granat, Satinder Samra, Núria Setó-Salvia, Argyro Alatza, Leela Phadke, Benjamin Galet and 9 more

Abstract read
In one paragraph

Article in Molecular neurodegeneration, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Oliver J ZiffDepartment of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, University College London, London, UK.ORCID 0000-0002-1504-7245
Gustavo Morrone ParfittDepartment of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.ORCID 0000-0003-0168-4099
Sarah JollyAlzheimer's Research UK UCL Drug Discovery Institute, University College London, London, UK.ORCID 0000-0003-1297-0058
Jackie M CaseyDepartment of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.ORCID 0000-0002-1447-8377
Lucy GranatAlzheimer's Research UK UCL Drug Discovery Institute, University College London, London, UK.ORCID 0000-0002-2767-9880
Satinder SamraAlzheimer's Research UK UCL Drug Discovery Institute, University College London, London, UK.
Núria Setó-SalviaDepartment of Clinical and Movement Neuroscience, Reta Lila Weston Institute, UCL Queen Square Institute of Neurology, London, UK.ORCID 0000-0002-3753-0027
Argyro AlatzaDepartment of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.ORCID 0000-0002-3342-6804
Leela PhadkeAlzheimer's Research UK UCL Drug Discovery Institute, University College London, London, UK.
Benjamin GaletSorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, APHP, Hôpital de la Pitié Salpêtrière, Paris, France.ORCID 0000-0002-3857-2886
Philippe RavassardSorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, APHP, Hôpital de la Pitié Salpêtrière, Paris, France.ORCID 0000-0002-0393-9262
Marie-Claude PotierSorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, APHP, Hôpital de la Pitié Salpêtrière, Paris, France.ORCID 0000-0003-2462-7150
John HardyDepartment of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.ORCID 0000-0002-3122-0423
Dervis A SalihUK Dementia Research Institute at UCL, London, UK.ORCID 0000-0001-7651-8998
Paul WhitingAlzheimer's Research UK UCL Drug Discovery Institute, University College London, London, UK.ORCID 0000-0002-4121-1379
Fiona DucotterdAlzheimer's Research UK UCL Drug Discovery Institute, University College London, London, UK.ORCID 0009-0000-6064-9088
Rickie PataniDepartment of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, University College London, London, UK.ORCID 0000-0002-3825-7675
Selina Wray *Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK. selina.wray@ucl.ac.uk.ORCID 0000-0003-3062-7050
Charles Arber *Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK. c.arber@ucl.ac.uk.ORCID 0000-0002-9743-8134

Funding

Alzheimer Society AS- JF- 18- 008Alzheimer's Research Trust ARUKSRF- 2016BMedical Research Council MR/M02492X/1UCLH Biomedical Research Centre UCLH Biomedical Research CentreUK Dementia Research Institute UK Dementia Research InstituteWellcome Institutional Strategic Support Fund WISSF3
6 · The paper itself

Abstract

backgroundMutations in PSEN1 cause familial Alzheimer's disease with almost complete penetrance. Age at onset is highly variable between different PSEN1 mutations and even within families with the same mutation. Current research into late onset Alzheimer's disease implicates inflammation in both disease onset and progression. PSEN1 is the catalytic subunit of γ-secretase, responsible for regulated intramembrane proteolysis of numerous substrates that include cytokine receptors. For this reason, we tested the hypothesis that mutations in PSEN1 impact inflammatory responses in astrocytes, thereby contributing to disease progression.

methodsWe developed patient-derived models of iPSC-astrocytes, representing three lines harbouring PSEN1 mutations and six control lines (including two isogenic controls). Transcriptomic and biochemical assays were used to investigate differential inflammatory responses to TNFα, IL1α and C1Q.

resultsWe show that PSEN1 is upregulated in response to inflammatory stimuli, and this upregulation is disrupted by pathological PSEN1 mutations. Using transcriptomic analyses, we demonstrate that PSEN1 mutant astrocytes have an augmented inflammatory profile in their basal state, concomitant with gene expression signatures revealing dysregulated intramembrane proteolysis and JAK-STAT signalling. Detailed investigation of the JAK-STAT2 signalling pathway showed reduced cell surface expression of IFNAR2, lower STAT2 phosphorylation cascades and delayed NFκB nuclear localisation in PSEN1 mutant astrocytes in response to inflammatory stimuli, thereby implicating the notion of altered cytokine signalling cascades. Finally, we use small molecule modulators of γ-secretase to confirm a role for PSEN1/γ-secretase in regulating the astrocytic response to inflammatory stimuli.

conclusionsTogether, these data suggest that mutations in PSEN1 enhance cytokine signalling via impaired regulated intramembrane proteolysis, thereby predisposing astrocytic inflammatory profiles. These findings support a two-hit contribution of PSEN1 mutations to fAD pathogenesis, not only impacting APP and Aβ processing but also altering the cellular response to inflammation.

Indexed as

Alzheimer DiseaseAstrocytesInflammationPresenilin-1HumansInduced Pluripotent Stem CellsMutationProteolysisSignal TransductionPresenilin-1PSEN1 protein, humanAlzheimer’s diseaseAstrocyteInflammationiPSCPSEN1Regulated intramembrane proteolysis

Identifiers

PMID40542358
PMCPMC12181884

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.